Immunometabolic Mechanisms of Blood Flow Restriction (BFR) Training After Anterior Cruciate Ligament Reconstruction

Description

This is a crossover phase 4 study to evaluate the impact of blood flow restriction on immunometabolism and gene expression in immune cells in individuals undergoing rehabilitation from anterior cruciate ligament reconstruction.

Conditions

Anterior Cruciate Ligament Reconstruction

Talk to us

Study Overview

On this page

Study Details

Study overview

This is a crossover phase 4 study to evaluate the impact of blood flow restriction on immunometabolism and gene expression in immune cells in individuals undergoing rehabilitation from anterior cruciate ligament reconstruction.

Immunometabolic Mechanisms of Blood Flow Restriction Training After Anterior Cruciate Ligament Reconstruction

Immunometabolic Mechanisms of Blood Flow Restriction (BFR) Training After Anterior Cruciate Ligament Reconstruction

Condition
Anterior Cruciate Ligament Reconstruction
Intervention / Treatment

-

Contacts and Locations

Milford

Yale New Haven Hospital, Milford, Connecticut, United States, 06461

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Provision of signed and dated informed consent form
  • 2. Stated willingness to comply with all study procedures and availability for two study visits at least 1 week apart
  • 3. All genders, between 18 and 60 years of age
  • 4. In good general health without any underlying medical conditions or prior injury that would place the subject at risk of further injury/illness by participating in the study
  • 1. Serious medical conditions including cardiovascular, metabolic (diabetes), rheumatologic, pulmonary, or musculoskeletal.
  • 2. Multiple ligament ruptures or trauma
  • 3. Rheumatoid arthritis or other significant comorbidities
  • 4. Lower extremity vascular pathology, including history of deep vein thrombosis
  • 5. Those with a history of sickle cell trait or disease
  • 6. Use of anticoagulant medications
  • 7. Pregnancy
  • 8. Treatment with another investigational drug or other intervention within one month of Study Day 1
  • 9. Current smoker or tobacco use within 3 months of Study Day 1
  • 10. Febrile illness within 2 weeks of Study Day 1

Ages Eligible for Study

18 Years to 60 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Yale University,

Rachel Perry, PhD, PRINCIPAL_INVESTIGATOR, Yale University

Study Record Dates

2025-04-01